Abstract
The Ca2+ channel blockers represent a successful group of therapeutic agents directed against cardiovascular targets, including hypertension and angina. These drugs, including the first-generation verapamil, nifedipine and diltiazem are directed against a subclass of voltage-gated Ca2+ channel - the L-type channel. Other subclasses of Ca2+ channel exist and are targets for new indications. The mechanisms of actions of the L-type blockers are discussed and the origins of their cardiovascular selectivity discussed. Although new drugs of this class directed against hypertension could be developed, there are both clinical and economic reasons that argue against such development. However, there are other possible targets to investigate where antagonists and activators of the L-type channel may be useful: such targets include fertility, neuronal growth, bone formation and epilepsy. Limitations to these approaches are discussed.
Keywords: Ca2+ channels, Ca2+ channel blockers, hypertension, angina, arrhythmias, neuronal Ca2+ channels, verapamil, diltiazem, nifedipine, 1, 4-dihydropyridines
Current Pharmaceutical Design
Title: L-Type Calcium Channels
Volume: 12 Issue: 4
Author(s): David J. Triggle
Affiliation:
Keywords: Ca2+ channels, Ca2+ channel blockers, hypertension, angina, arrhythmias, neuronal Ca2+ channels, verapamil, diltiazem, nifedipine, 1, 4-dihydropyridines
Abstract: The Ca2+ channel blockers represent a successful group of therapeutic agents directed against cardiovascular targets, including hypertension and angina. These drugs, including the first-generation verapamil, nifedipine and diltiazem are directed against a subclass of voltage-gated Ca2+ channel - the L-type channel. Other subclasses of Ca2+ channel exist and are targets for new indications. The mechanisms of actions of the L-type blockers are discussed and the origins of their cardiovascular selectivity discussed. Although new drugs of this class directed against hypertension could be developed, there are both clinical and economic reasons that argue against such development. However, there are other possible targets to investigate where antagonists and activators of the L-type channel may be useful: such targets include fertility, neuronal growth, bone formation and epilepsy. Limitations to these approaches are discussed.
Export Options
About this article
Cite this article as:
Triggle J. David, L-Type Calcium Channels, Current Pharmaceutical Design 2006; 12(4) . https://dx.doi.org/10.2174/138161206775474503
DOI https://dx.doi.org/10.2174/138161206775474503 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Editorial (Thematic Issue: Measurements of ABC Transporters at the Blood-Brain Barrier: Novel Methods and Applications)
Current Pharmaceutical Design Restless Legs Syndrome in Multiple Sclerosis
CNS & Neurological Disorders - Drug Targets Phentermine and Topiramate Extended-Release for the Obesity: New Kids on the Block
Recent Patents on Cardiovascular Drug Discovery Treatment of Estrogen Receptor-Positive Breast Cancer
Current Medicinal Chemistry Recent Highlights on Molecular Hybrids Potentially Useful in Central Nervous System Disorders
Mini-Reviews in Medicinal Chemistry <i>In Silico</i> Study Examining New Phenylpropanoids Targets with Antidepressant Activity
Current Drug Targets α7-Nicotinic Acetylcholine Receptors: An Old Actor for New Different Roles
Current Drug Targets Treating Rapid Cycling Bipolar Disorder with Novel Medications
Current Psychiatry Reviews Central Nervous System Acting Drugs in Treatment of Migraine Headache
Central Nervous System Agents in Medicinal Chemistry Current Status of Complementary and Alternative Medicine in the Treatment of Rheumatic Disease Pain
Current Rheumatology Reviews Synthesis, Neurotoxicity and Anticonvulsant Study of Some Benzothiazole Analogs
Letters in Drug Design & Discovery Recent Advancement in Computer-Aided Drug Design
Current Pharmaceutical Design Recent Advancements in Nanodiamond Mediated Brain Targeted Drug Delivery and Bioimaging of Brain Ailments: A Holistic Review
Pharmaceutical Nanotechnology Subject Index to Volume 1
Current Neurovascular Research The Hypothalamus and Obesity
Recent Patents on CNS Drug Discovery (Discontinued) Catatonia, Malignant Catatonia, and Neuroleptic Malignant Syndrome
Current Psychiatry Reviews Mitochondrial Dysfunction and Targeted Drugs: A Focus on Diabetes
Current Pharmaceutical Design The Metabotropic Glutamate Receptors: Structure, Activation Mechanism and Pharmacology
Current Drug Targets - CNS & Neurological Disorders An Updated Unified Pharmacophore Model of the Benzodiazepine Binding Site on γ-Aminobutyric Acida Receptors: Correlation with Comparative Models
Current Medicinal Chemistry Critical Review on the Chemical Aspects of Cannabidiol (CBD) and Harmonization of Computational Bioactivity Data
Current Medicinal Chemistry